Causes of mortality after dose-escalated radiation therapy and androgen deprivation for high-risk prostate cancer.
暂无分享,去创建一个
J. Ciezki | C. Reddy | E. Klein | P. Kupelian | A. Mahadevan | A. Stephenson | M. Abdel-Wahab | K. Stephans | R. Tendulkar | G. Hunter
[1] Charles A Enke,et al. Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. , 2012, Journal of the National Comprehensive Cancer Network : JNCCN.
[2] J. Ciezki,et al. Redefining high-risk prostate cancer based on distant metastases and mortality after high-dose radiotherapy with androgen deprivation therapy. , 2012, International journal of radiation oncology, biology, physics.
[3] H. Sandler,et al. Continued benefit to androgen deprivation therapy for prostate cancer patients treated with dose-escalated radiation therapy across multiple definitions of high-risk disease. , 2011, International journal of radiation oncology, biology, physics.
[4] A. Jemal,et al. Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.
[5] Matthew R Cooperberg,et al. Time trends and local variation in primary treatment of localized prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] R. Weichselbaum,et al. Dose-escalated radiotherapy for high-risk prostate cancer: outcomes in modern era with short-term androgen deprivation therapy. , 2009, International journal of radiation oncology, biology, physics.
[7] D. Grignon,et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] M. Parmar,et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. , 2007, The Lancet. Oncology.
[9] Daniel W. Miller,et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. , 2005, JAMA.
[10] James A Hanley,et al. Prostate cancer and the Will Rogers phenomenon. , 2005, Journal of the National Cancer Institute.
[11] D. Grignon,et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. , 2005, International journal of radiation oncology, biology, physics.
[12] Jacques Bernier,et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial , 2002, The Lancet.
[13] Robert Gray,et al. A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .
[14] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[15] Lei Dong,et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. , 2008, International journal of radiation oncology, biology, physics.
[16] C. Mackenzie,et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.
[17] D. Cox. Regression Models and Life-Tables , 1972 .